Ledipasvir

Basic Information


CAS ID: 1256388-51-8
Molecular Formula: C49H54F2N8O6
Molecular Weight: 889 g/mol
Monoisotopic Mass: 888.4134 g/mol
Class: Small Molecule
Natural Product: No
Other Names: LEDIPASVIR | GS-5885
Analysis: Drug repositioning mechanism analysis

O O NH O N N NH F F NH N N O NH O O


Compound Structure and Identifier


InChI: InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1 See All
InChI Key: VRTWBAAJJOHBQU-KMWAZVGDSA-N
Smiles: COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c3nc(c[nH]3)c4ccc5c6ccc(cc6C(F)(F)c5c4)c7ccc8[nH]c(nc8c7)[C@@H]9[C@H]%10CC[C@H](C%10)N9C(=O)[C@@H](NC(=O)OC)C(C)C See All
Molfile: Download


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT02705534 Disease Liver fibrosis
Phase Phase 3 Status Completed
First Received March 10, 2016 Last Verified April 30, 2018
Sponsor Tehran University of Medical Sciences

Trial Record 2

ClinicalTrial ID NCT02597166 Disease Liver fibrosis
Phase Phase 3 Status Completed
First Received November 5, 2015 Last Verified October 25, 2018
Sponsor University Health Network, Toronto

Related Link


PubChem: 67505836
ChEMBL: CHEMBL2374220